|
Mike Mullen has a distinguished track record of creating value through mergers and acquisitions and operational improvements. He became Magellan’s chief financial officer in the summer of 2006 after more than 20 years’ finance and operations experience in private equity and global life-science manufacturing and services companies. Most recently, Mr. Mullen was chief financial officer and partner in JMH Capital, a private-equity firm where he raised more than $100 million from a diverse group of investors and closed four portfolio investments; and before that, Magellan Discovery Technologies, where he negotiated deals on acquisition targets with revenues ranging from $5 million to $400 million. Previously, Mr. Mullen was chief financial officer and director of integration for the $350+ million Analytical Instrument business of PerkinElmer, Inc., a provider of scientific instruments, consumables, and services. Mr. Mullen also served as controller of Thermo Optek, a publicly traded subsidiary of Thermo Electron and manufacturer of spectroscopy instrumentation for molecular and elemental analysis with revenues of $520 million. A certified public accountant, Mr. Mullen received his BBA from James Madison University. Mr. Mullen is a director and chair of the Audit Committee of Boston Life Sciences, Inc., an R&D development-stage biopharmaceutical company. He is also a marathon runner and fund raiser for Brigham and Women’s Hospital in Boston. | 